Last updated on April 2019

Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis


Brief description of study

The objective of this study is to investigate the safety and efficacy of administering 372.6 mg of AK1820 (isavuconazonium sulfate) intravenously or orally to adult Japanese patients with deep mycosis. The primary endpoint is safety (percentage of patients with adverse events after starting the study treatment).

Clinical Study Identifier: NCT03471988

Find a site near you

Start Over

Research site

Yokohama, Japan
0.36miles
  Connect »

Research site

Naka-Ku, Japan
1.47miles
  Connect »

Research site

Kawasaki, Japan
6.69miles
  Connect »